Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

CCN2 - Exploring a New Biomarker in Myelofibrosis

Ardaman Shergill, MD, Santosh L. Saraf, MD, Sujata Gaitonde, MD FCAP, Damiano Rondelli, MD, Irum Khan, MD

Blood (2015) 126 (23): 4063.

https://doi.org/10.1182/blood.V126.23.4063.4063

Published: 2015

Journal Articles

A Preclinical Non-Human Primate Model to Test Reversible Myeloablation Following IV Busulfan Therapy without Stem Cell Rescue

Nadim Mahmud, MD PhD, Amit Khanal, MD, Simona Taioli, MS, Emre Koca, MD, Sujata Gaitonde, MD FACP, Benjamin Petro, BS, Karen Sweiss, PharmD, Damiano Rondelli, MD

Blood (2015) 126 (23): 1868.

https://doi.org/10.1182/blood.V126.23.1868.1868

Published: 2015

Journal Articles

FOXM1 Binds Nucleophosmin in AML and Confers Resistance to Chemotherapy

Irum Khan, MD, Maryam Zia, MD, Marianna Halasi, PhD, Peter Gann, MD, ScD, Sujata Gaitonde, MD FACP, Andrei Gartel, PhD

Blood (2015) 126 (23): 2467.

https://doi.org/10.1182/blood.V126.23.2467.2467

Published: 2015

Journal Articles

Conjunctival Biopsy to Guide Treatment of Chronic Ocular Gvhd

Pritesh R. Patel, MB, ChB, Sonal Ghandi, MD, Snehal Sonawane, MD, Sapna Tibrewal, MD, Saumad Jassim, MD, Sujata Gaitonde, MD, Santosh L Saraf, MD, Sandeep Jain, MD, Damiano Rondelli, MD

Blood (2012) 120 (21): 4491.

https://doi.org/10.1182/blood.V120.21.4491.4491

Published: 2012

Journal Articles

Evaluation of Genotoxicity of Chromatin Modifying Agents Expanded Hematopoietic Graft in a Non-Human Primate Model.

Simona Taioli, MS, Benjamin Petro, BS, Sujata Gaitonde, MD, John G. Quigley, MD, Valerie Lindgren, PhD, Manuel Borce, MS, Karen Sweiss, PharmD, Damiano Rondelli, MD, Nadim Mahmud, MD, PhD

Blood (2012) 120 (21): 2994.

https://doi.org/10.1182/blood.V120.21.2994.2994

Published: 2012

Journal Articles

Is Splenectomy Necessary in Patients with Myelofibrosis and Extensive Splenomegaly Prior to Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning Regimens?.

Stefan O. Ciurea, MD, Barry Sadegi, MD, Andrew Wilbur, MD, Victoria Alagiozian-Angelova, MD, Sujata Gaitonde, MD, Lisa C. Dobogai, RN, NP, Luke P. Akard, MD, Ronald Hoffman, MD, Damiano Rondelli, MD

Blood (2007) 110 (11): 1091.

https://doi.org/10.1182/blood.V110.11.1091.1091

Published: 2007

NARROW

CCN2 - Exploring a New Biomarker in Myelofibrosis

A Preclinical Non-Human Primate Model to Test Reversible Myeloablation Following IV Busulfan Therapy without Stem Cell Rescue

FOXM1 Binds Nucleophosmin in AML and Confers Resistance to Chemotherapy

Conjunctival Biopsy to Guide Treatment of Chronic Ocular Gvhd

Evaluation of Genotoxicity of Chromatin Modifying Agents Expanded Hematopoietic Graft in a Non-Human Primate Model.

Is Splenectomy Necessary in Patients with Myelofibrosis and Extensive Splenomegaly Prior to Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning Regimens?.

Email alerts

ASH Publications

American Society of Hematology

CCN2 - Exploring a New Biomarker in Myelofibrosis

A Preclinical Non-Human Primate Model to Test Reversible Myeloablation Following IV Busulfan Therapy without Stem Cell Rescue

FOXM1 Binds Nucleophosmin in AML and Confers Resistance to Chemotherapy

Conjunctival Biopsy to Guide Treatment of Chronic Ocular Gvhd

Evaluation of Genotoxicity of Chromatin Modifying Agents Expanded Hematopoietic Graft in a Non-Human Primate Model.

Is Splenectomy Necessary in Patients with Myelofibrosis and Extensive Splenomegaly Prior to Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning Regimens?.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only